Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...
Doctors may soon have a new tool in the fight against one of the most aggressive and lethal forms of cancer—in the form of an 'early warning' signature of precancerous cells. This is the promise of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results